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S U M M A R Y
Background: A Mycobacterium parascrofulaceum strain was isolated from a pneumonia patient—the ﬁrst
such reported case from China. The bacteriological characteristics of the strain were determined.
Methods: Species identiﬁcation was performed by homologue gene sequence comparison, then a series
of biochemical tests was conducted to elucidate the bacteriological characteristics. Drug susceptibility
and pathogenicity to mice of the strain were tested.
Results: The clinical M. parascrofulaceum strain presented a very similar phenotypic proﬁle to that of
Mycobacterium scrofulaceum. The M. parascrofulaceum strain was sensitive to rifabutin, rifapentine,
clarithromycin, azithromycin, cefoxitin, and moxiﬂoxacin in vitro. At week 2 post-infection, the lung
tissues of mice demonstrated a local inﬂammatory response denoted by peri-bronchiolar inﬂammatory
inﬁltrates. At weeks 4 and 8, the lung tissues showed peri-bronchiolar inﬂammatory inﬁltrates with
large aggregates of lymphocytes and part of the tissue showed granulomatous lesions; there was no
appreciable necrosis. The colony-forming units (CFU) count of infected lung and spleen increased
gradually during the 8 weeks of the experiment.
Conclusions: The M. parascrofulaceum strain isolated in China was sensitive to rifabutin, rifapentine,
clarithromycin, azithromycin, cefoxitin, and moxiﬂoxacin. The mycobacteria were capable of
proliferating in mice and could lead to pathological changes in the lungs of the mice.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The most common mycobacterial infection in the world is
caused by Mycobacterium tuberculosis, however there are increas-
ing reports of non-tuberculous mycobacterial (NTM) infection,1
and about 150 NTM species have been reported to date.2 NTM are
environmental pathogens distributed via water, wet soil, house
dust, dairy products, cold-blooded animals, vegetation, and human
feces, amongst other means.3 As the clinical presentation of NTM
infection is often difﬁcult to differentiate from that of M.* Corresponding authors. Tel.: +86 10 89509159; fax: +86 10 89509359.
E-mail addresses: suhuazheng0264@sina.com (S.-H. Zheng),
hairong.huangcn@gmail.com (H.-R. Huang).
1 Tel.: +86 10 89509371.
2 These authors contributed equally to this article.
http://dx.doi.org/10.1016/j.ijid.2014.01.023
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).tuberculosis complex, the accurate and timely identiﬁcation of
NTM in the laboratory is a critical step before appropriate
treatments can be implemented.4
Mycobacterium parascrofulaceum, a newly deﬁned species of
NTM belonging to group II,4 was ﬁrst reported by Turenne et al.5 in
2004. A total nine cases of infection with this bacterium have been
reported to date,6–11 including one Chinese case of cutaneous
infection in 2012. Similar to many other NTM species, M.
parascrofulaceum is an opportunistic pathogen,5 and the most
likely candidates for infection are hosts that have underlying co-
morbidities or immune paresis. The previous literature has focused
on the clinical presentation of the cases, but has not included a
detailed bacteriological characterization and description of the
isolates.
An M. parascrofulaceum strain was isolated from a pneumonia
patient presenting in 2008, but although the genus was known, the
species was only recently identiﬁed by our team. This case mightciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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infection reported from China. In this study, we aimed to
determine the bacteriological characteristics of the M. parascro-
fulaceum strain.
2. Methods
2.1. Patient and strain information
The strain was acquired from the sputum specimen of a 47-
year-old male patient with pneumonia in an epidemiological study
in China in 2008. Written informed consent for participation was
obtained from all the patients in the epidemiological study. A total
of 4069 clinical isolates were enrolled in the survey, and among
them, 140 were deﬁned as NTM stains; only one M. parascroful-
aceum was eventually identiﬁed. The patient lived in Fujian
Province (located in the south-east of China, close to the ocean) and
worked at a government institution. He had a cough and
expectoration for 3 weeks before consulting a doctor. The patient
had no fever, no chest pain, and no sweating. His X-ray showed
signs of pneumonia, and acid-fast staining of all three consecutive
sputum samples obtained showed acid-fast bacilli (AFB). The
patient had been diagnosed with pulmonary tuberculosis 2 years
previously and had been cured following 6 months of ﬁrst-line
anti-tuberculosis drug regimen treatment. Whether the patient
had complications like diabetes or other immune suppression
diseases was not known.
Unfortunately, we could not trace the patient from whom the
M. parascrofulaceum strain was isolated. As the species identiﬁca-
tion was performed long after sputum sample collection, patient
follow-up was not successful. A Capilia Test (TAUNS, Numazu,
Japan) was performed to rule out co-infection with M. tuberculosis
(data not shown), and given that M. parascrofulaceum is not among
the list of the usual species for contamination when conducting
culture, and three consecutive sputum samples from our patient
were all AFB-positive (from which the M. parascrofulaceum strain
was cultured), we suggest that the M. parascrofulaceum may have
been the causative pathogen of pneumonia in our patient with AFB
smear-positive sputa.
2.2. Species identiﬁcation by homologous gene sequence comparison
The 16S rRNA,12,13 16–23S rRNA gene internal transcribed
spacer (ITS),14,15 and hsp65 sequences16 were used for species
identiﬁcation, with tests performed as described previously. The
PCR products were sent to a commercial laboratory for sequencing
and the sequences were analyzed using BLAST at http://
www.ncbi.nlm.nih.gov.
2.3. Phenotypic properties
A series of standard biochemical tests for Mycobacterium
characterization were performed, as described by Kent PT and
Kubica GP17 including a growth test, nitrate reductase assay,
arylsulfatase assay, tellurite reductase assay, Tween hydrolysis
assay, urease assay, and media growth test with 50 mg/ml para-
aminobenzoic acid (PNB), 10 mg/ml thiophene carboxylic acid
(TCH), 5% NaCl, or MacConkey agar. Quality control was performed
using reference strains Mycobacterium scrofulaceum ATCC 19981,
Mycobacterium simiae ATCC 25275, Mycobacterium intracellulare
ATCC 13950, and Mycobacterium avium ATCC 25291.
2.4. Drug susceptibility testing (DST)
Susceptibility testing was performed using the serial two-fold
broth microdilution method, and the minimum inhibitory concen-tration (MIC) of 23 drugs for the strain was determined by microplate
Alamar blueassay.18,19The antimicrobial reagentsemployedwereall
purchased from Sigma Aldrich (St. Louis, MO, USA): rifampin,
ethambutol, isoniazid, amikacin, sulfamethoxazole, oﬂoxacin, para-
aminosalicylic acid, rifapentine, capreomycin, cefoxitin, imipenem,
minocycline, doxycycline, clarithromycin, azithromycin, merope-
nem, trimethoprim, rifabutin, linezolid, streptomycin, ethionamide,
moxiﬂoxacin, and levoﬂoxacin. The reference strain Mycobacterium
tuberculosis H37Rv ATCC 27294 was used as control.
2.5. Cell wall mycolic acid composition analysis
The composition and structure analysis of the cell wall mycolic
acids was performed by high-performance liquid chromatography
(HPLC) in accordance with the instructions of the Sherlock
Mycobacteria Identiﬁcation System (SMIS; MIDI, Inc. Newark,
Delaware USA). Brieﬂy, the mycolic acids were cleaved from the
cells by saponiﬁcation before being extracted with chloroform, and
were then derivatized to ﬂuorescence-absorbing bromophenacyl
esters and applied to the HPLC (Agilent 1200). The reference strains
M. intracellulare ATCC13950, M. avium ATCC 25291, M. scrofulaceum
ATCC 19981, and M. simiae ATCC 25273 were used as controls.
2.6. Pathogenicity analysis of the strain in mice
Infection with M. parascrofulaceum was evaluated among 6- to
8-week-old female C57BL/6 mice. The mice were kept in sterile
isolators in the biohazard animal unit of a biosafety level 3 (BSL-3)
laboratory. A total of 72 mice were divided evenly into six groups.
The mice were challenged with 0.1 ml of M. parascrofulaceum
suspension containing approximately 1  107 bacilli. The M.
tuberculosis laboratory strain H37Rv was used as a control strain,
while phosphate-buffered saline (PBS) was used as negative
control. Groups 1, 3, and 5 were inoculated via the tail vein with M.
parascrofulaceum, H37Rv, and PBS, respectively. Groups 2, 4, and 6
were injected intraperitoneally with M. parascrofulaceum, H37Rv,
and PBS, respectively.
Bacterial loads in the lungs and spleens of the infected mice, as
well as the control mice, were evaluated at weeks 2, 4, and 8 post-
challenge. At every time point, four mice were sacriﬁced and the left
lungs and half of the spleens were homogenized in 1 ml PBS
containing 0.04% Tween 20. Ten-fold serial dilutions of homo-
genates wereplated in duplicateontoMiddlebrook7H10agar plates
supplemented with 10% oleic acid, albumin, dextrose and catalase
(OADC) and incubated at 37 8C for 1 month. The colony counts were
expressed in log10. The right lung and half of the spleen from each
mouse were ﬁxed with 10% formalin in PBS and then subjected to
standard processing and parafﬁn embedding. Multiple 4-mm-thick
tissue sections were stained with hematoxylin and eosin (H&E) for
the histological/morphometric analysis. The histological character-
istics of exudative and proliferative reactions were classiﬁed based
on the criteria described previously.20
2.7. Statistical analysis
The Student’s t-test was used to assess statistical signiﬁcance




Analysis of the 16S rRNA, ITS, and hsp65 sequences of the isolate
using BLAST against sequences from the GenBank database gave
99.64%, 99.06%, and 99.83% similarity, respectively, with that of the
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Rifabutinb 0.016–8 0.25 0.5
Rifapentinea 0.03–16 0.5 2
Clarithromycinb 0.125–64 0.25 1
Cefoxitinb 0.125–64 64 64
Azithromycinc 0.25–1024 16 128
Moxiﬂoxacina 0.03–16 0.5 0.5
Rifampicina 0.125–64 2 1
Levoﬂoxacina 0.0625–32 4 2
Isoniazida 0.0625–128 >128 0.1
Streptomycina 0.25–128 8 1
Amikacina 0.03–16 8 1
Oﬂoxacina 0.0625–32 8 2
para-Aminosalicylic acida 0.0625–32 >32 2
Ethionamidea 0.039–40 >40 5
Capreomycina 0.25–128 32 2.5
Ethambutola 0.25–128 >128 5
Imipenemb 0.25–128 32 8
Minocyclinec 0.0625–32 >32 2
Doxycyclineb 0.03–16 >16 8
Meropenemc 0.03–16 >16 1
Linezolida 0.03–16 8 1
Sulfamethoxazoleb 0.3125–160 >160 19
Trimethoprimb 0.125–64 >64 1
MIC, minimum inhibitory concentration; MABA, microplate Alamar blue assay;
WHO, World Health Organization; TB, tuberculosis; CLSI, Clinical and Laboratory
Standards Institute.
a The WHO recommended critical concentrations of these antimicrobial drugs for
TB.
b The CLSI recommended critical concentrations for rapidly growing mycobac-
teria.
c The critical concentrations for TB proposed by Brown et al.,21 Watt et al.22, and
Hugonnet et al.23
Table 1
Phenotypic characteristics of the Mycobacterium parascrofulaceum clinical strain in comparison with other slowly growing Mycobacterium speciesa
Characteristic M. parascrofulaceum M. intracellulare M. avium M. scrofulaceum
Growth at
25 8C +++ +++ +++ +++
37 8C +++ +++ +++ +++
Visible growth in
<7 days    
>7 days + + + +
Morphology Smooth Smooth Smooth Smooth
Pigments produced Yellow White White Yellow
Nitrate reductase    
Arylsulfatase
3 days    
14 days  +  +
Tellurite reductase + + + 
Tween hydrolysis
<5 days    
<10 days    
Urease +   +
Growth with
10 mg TCH/ml +++ +++ +++ +++
50 mg PNB/ml +++ +++ +++ +++
5% NaCl +++ +++ +++ +++
Growth on MacConkey agar    
TCH, thiophene carboxylic acid; PNB, para-aminobenzoic acid.
a +++, Highest level of growth; ++, higher level of growth; +, positive result or modest growth; , negative result or no growth.
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M. simiae were 98.57%, 95.88%, and 93.27%, respectively, and M.
scrofulaceum were 93.39%, 94.41%, and 91%, respectively. The 16S
rRNA, ITS, and hsp65 sequences of our isolate are available in
GenBank under accession numbers KF938687–KF938689.
3.2. Phenotypic features of the strain
Microscopic examination showed generally pleomorphic acid-
fast bacilli with moderate beading. Vigorous growth was observed
when the bacteria were grown at both 25 8C and 37 8C, but more
colonies and earlier growth were seen when cultured at 37 8C.
Colonies grown on Middlebrook 7H10 agar were smooth, domed,
and scotochromogenic with yellow to orange pigmentation. The
strain could hydrolyze urea and reduce telluride, but could not
hydrolyze Tween 80 nor reduce nitrates or hydrolyze arylsulfatase
within 3 days. The strain could tolerate 5% NaCl, 10 mg/ml TCH, or
500 mg/ml PNB enrichment in the medium. Culture and biochem-
ical characteristics of the M. parascrofulaceum isolate and its closely
related slowly growing mycobacterial species are shown in Table 1.
3.3. Drug susceptibility testing
According to the World Health Organization (WHO) recom-
mended critical concentrations for M. tuberculosis, the Clinical and
Laboratory Standards Institute (CLSI) recommended critical con-
centrations for rapidly growing mycobacteria, and some refer-
ences,21–23 the M. parascrofulaceum isolate was sensitive to
rifabutin, rifapentine, clarithromycin, azithromycin, cefoxitin,
and moxiﬂoxacin, while resistant to isoniazid, streptomycin,
ethambutol, rifampin, amikacin, oﬂoxacin, levoﬂoxacin, para-
aminosalicylic acid, ethionamide, capreomycin, imipenem, mino-
cycline, doxycycline, meropenem, linezolid, sulfamethoxazole, and
trimethoprim (Table 2).
3.4. Mycolic acid pattern analyzed by SMIS
HPLC analysis of the mycolic acid content showed the closest
match with the Mycobacterium intracellulare–avium–scrofulaceum
complex, with a similarity index (SI) of 0.86. By Sherlock software
matching, the mycolic acid pattern of the M. parascrofulaceumisolate identiﬁed it as one of the Mycobacterium-MAIS complex
(Figure 1).
3.5. Bacterial loads in C57BL/6 mice
The strain was capable of proliferating in C57BL/6 mice by
manifesting increasing numbers of CFU in both the lungs and
spleens over the course of 8 weeks post-infection. Mice infected
Figure 1. Mycolic acid patterns of Mycobacterium parascrofulaceum compared with those of MAIS complex (M. avium, M. intracellulare, and M. scrofulaceum) obtained by HPLC
analysis using Sherlock software. The blue line represents the pattern of M. parascrofulaceum, while the red one represents the pattern of MAIS.
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infected with H37Rv at 2 and 4 weeks post-infection, but at 8
weeks post-infection the bacterial burden was lower in the M.
parascrofulaceum-infected mice (p < 0.05) (Figure 2). Results
were similar in mice infected either via the tail vein or
intraperitoneally.
3.6. Lung and spleen histopathology in C57BL/6 mice
After ﬁxation, the tissues of the mice were sectioned and
stained with H&E and microscopic examination was performed.
Two weeks post-challenge, the lung tissues demonstrated a local
inﬂammatory response denoted by peri-bronchiolar inﬂammatory
inﬁltrates. At weeks 4 and 8 post-infection, lung tissues showed










































Figure 2. Growth curve of tested bacilli in the lungs and spleens of C57BL/6 mice. The C57
or tail vein (C, D) route. Data are presented as the mean and standard deviation at each tim
H37Rv strain.lymphocytes and part of the tissue showed granulomatous lesions;
no appreciable necrosis was apparent (Figure 3). The histopatho-
logical features of tissue from animals infected with either M.
parascrofulaceum or H37RV were indistinguishable. In spite of the
severe pathological changes observed in the lungs of the infected
mice, all the animals maintained viability for up to 8 weeks of
observation.
4. Discussion
M. parascrofulaceum has shown similarities to several known
NTM species using single identiﬁcation methods, but it is clearly a
unique species as determined by a polyphasic approach. Tortoli
et al. reported that about 10% of M. scrofulaceum isolates were
































BL/6 mice were inoculated with 1  107 bacilli either through intraperitoneal (A, B)
e-point. *Statistically signiﬁcant (p < 0.05) when compared with mice infected with
Figure 3. Histological pictures of the lungs in C57BL/6 mice by H&E staining at week 4 post-infection. (A) Negative control mice. (B) M. parascrofulaceum-infected mice,
through tail vein route. (C) H37Rv-infected mice, through tail vein route. (D) M. parascrofulaceum-infected mice, through intraperitoneal route. (E) H37Rv-infected mice,
through intraperitoneal route. Original magniﬁcation: 40.
G. Liu et al. / International Journal of Infectious Diseases 25 (2014) 82–8786parascrofulaceum strain was identiﬁed as Mycobacterium-MAIS
complex by the mycolic acid analysis method. Therefore, we
suggest the only reliable way to identify M. parascrofulaceum is by
sequence comparison of highly conserved genes.
Genetically, M. parascrofulaceum is most related to M. simiae,
whereas it presents a similar phenotypic proﬁle to M. scroful-
aceum.5 In our assays, the M. parascrofulaceum strain had almost
the same phenotypic proﬁle as the M. scrofulaceum type strain
when considering all the biochemical tests, except for the tellurite
reductase assay and the 14-day arylsulfatase assay. Although its
phenotypic proﬁle was also similar to those of M. intracellulare and
M. avium, the urease, tellurite reductase, and arylsulfatase assays
were helpful in differentiating them.
The prognosis of M. parascrofulaceum infection remains unclear.
Although anti-mycobacterial drugs have been used historically in
the few clinical cases reported, most of the patients died before a
reasonable evaluation of the treatment could be made. In three
known M. parascrofulaceum infection cases in which the patient
survived, one case improved by administering clarithromycin,
ethambutol, and rifampin,5 the second did not show recurrence
after a surgical debridement of the pathological lesions in the lung
and lymph node without any chemotherapy,8 and the third slowly
improved by administering clarithromycin, amikacin, and etham-
butol.9 Turenne et al. showed that M. parascrofulaceum isolates
were sensitive to rifampin, clarithromycin, amikacin, and sulfa-
methoxazole in vitro,5 and Teruya et al. suggested that rifampin,
clarithromycin, and levoﬂoxacin could be effective for M. para-
scrofulaceum infection,8 while Shojaei et al. showed that the
organism was susceptible to amikacin, clarithromycin, rifampin,
doxycycline, sulfamethoxazole, streptomycin, and imipenem in
vitro.10 In this study, we tested the sensitivity of the organism to 23
agents including the commonly used anti-tuberculosis drugs and
some general antibiotics that are frequently used in the treatment
of NTM disease. The results showed that this isolate was
susceptible to rifabutin, rifapentine, clarithromycin, azithromycin,
cefoxitin, and moxiﬂoxacin in vitro. The other M. parascrofulaceum
strain isolated from a cutaneous infection in China was reported to
be sensitive to clarithromycin and moxiﬂoxacin, which is
consistent with our ﬁndings. In our test, the MIC of the strain to
rifampin was 2 mg/ml, and we deﬁne the strain as resistant
according to the critical concentration recommended by the WHO
for M. tuberculosis. However, as the MIC is so close to the critical
concentration, administering rifampin might also be effective in
clinical treatment. The levoﬂoxacin MIC was similarly close to the
critical concentration. The discrepancy in DST between our isolate
and those reported in the literature may be due to strain
differences. According to the previous reports and our results,
rifamycin agents, clarithromycin, azithromycin, moxiﬂoxacin, and
levoﬂoxacin may be the key drugs for the treatment of M.
parascrofulaceum infection.
Owing to its relatively recent recognition as a novel species, not
much is known about the pathogenicity of M. parascrofulaceum.Our mouse infection model results at least suggest that M.
parascrofulaceum is capable of proliferating in mice and could lead
to pathological changes in the lungs but not in the spleens of the
mice.
In conclusion, an M. parascrofulaceum strain isolated from a
Chinese pneumonia patient was sensitive to rifabutin, rifapentine,
clarithromycin, azithromycin, cefoxitin, and moxiﬂoxacin, was
capable of proliferating in mice, and could lead to pathological
changes in the lungs of the mice.
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